Updated Jul 16, 2026
Smith Karen L. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $44K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-06-12 | SGMO | SANGAMO THERAPEUTICS, INC | A — Grant or award | 25.0K | $0.00 | |
| 2024-11-25 | AUPH | Aurinia Pharmaceuticals Inc. | A — Grant or award | 12.1K | $0.00 | |
| 2024-11-12 | AUPH | Aurinia Pharmaceuticals Inc. | S — Open-market sale | 5.2K | $8.43 | $44K |
| 2024-11-12 | AUPH | Aurinia Pharmaceuticals Inc. | M — Option exercise | 17.9K | — |
Smith Karen L. is a corporate insider — currently tracked as Director of Context Therapeutics Inc. (CNTX). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($44K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Smith Karen L. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.